Medical sector’s Neuronetics Stock Forecast, Price & News’s (NASDAQ:STIM) Buy rating Reiterated by JMP Securities

Neuronetics Stock Forecast, Price & News (NASDAQ:STIM)‘s stock had its Buy rating Reiterated by by analysts at $12.00 in a research report issued to clients and investors.

View More Medical sector’s Neuronetics Stock Forecast, Price & News’s (NASDAQ:STIM) Buy rating Reiterated by JMP Securities

Turning Point Therapeutics (TPTX) Downgraded by JMP Securities to Market Perform

Turning Point Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Turning Point Therapeutics Downgraded by JMP Securities on 10-11-21. In a note to investors, the firm issued a new rating of Market Perform. The analysts previously had rating of Outperform.

View More Turning Point Therapeutics (TPTX) Downgraded by JMP Securities to Market Perform

Adamas Pharmaceuticals (ADMS) Downgraded by JMP Securities to Market Perform

Adamas Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Adamas Pharmaceuticals Downgraded by JMP Securities on 10/11/2021. In a note to investors, the firm issued a new rating of Market Perform. The analysts previously had rating of N/A.

View More Adamas Pharmaceuticals (ADMS) Downgraded by JMP Securities to Market Perform